🇺🇸 Sigmart (nicorandil) in United States

122 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 122

Most-reported reactions

1. Condition Aggravated — 19 reports (15.57%)
2. Cardiac Failure — 18 reports (14.75%)
3. Blood Pressure Decreased — 12 reports (9.84%)
4. Anaemia — 11 reports (9.02%)
5. Aspartate Aminotransferase Increased — 11 reports (9.02%)
6. Depressed Level Of Consciousness — 11 reports (9.02%)
7. Hepatic Function Abnormal — 11 reports (9.02%)
8. Alanine Aminotransferase Increased — 10 reports (8.2%)
9. Interstitial Lung Disease — 10 reports (8.2%)
10. Blood Creatine Phosphokinase Increased — 9 reports (7.38%)

Source database →

Frequently asked questions

Is Sigmart (nicorandil) approved in United States?

Sigmart (nicorandil) does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Sigmart (nicorandil) in United States?

Merck KGaA, Darmstadt, Germany is the originator. The local marketing authorisation holder may differ — check the official source linked above.